OPTIC: A Phase II Dose-Optimization Trial Evaluating 3 Different Starting Doses of Ponatinib in CP-CML

June 4-8, 2021; Online at https://conferences.asco.org/am
Results from this study suggest that the benefit–risk profile of ponatinib is optimized by starting at a dose of 45 mg/day and reducing the dose to 15 mg/day upon achieving response (≤1% BCR-ABL1IS).
Format: Microsoft PowerPoint (.ppt)
File Size: 461 KB
Released: June 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Clinical Care Options (CCO): Expert review of key data in MDS and MPN from the 2021 ASH annual meeting

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Clinical Care Options (CCO): Experts John M. Burke, MD, and Peter Martin, MD, review key data in lymphomas and CLL presented at the 2021 American Society of Hematology Annual Meeting

John M. Burke, MD Peter Martin, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 10, 2022 Expired: May 9, 2023

Enter characteristics of your patient with myelodysplastic syndrome (MDS) into this online tool to receive treatment recommendations from 5 experts.

Rami S. Komrokji, MD
Program Director
Amy E. DeZern, MD, MHS Daniel Pollyea, MD, MS Michael J. Savona, MD Amer Zeidan, MBBS
Released: May 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings